Treatment of Obsessive-Compulsive Disorder

计划入组 74 人 · 首次发布于 1999 年 11 月 3 日

Cohort Study of Obsessive-Compulsive Disorder

计划入组 500 人 · 首次发布于 2026 年 9 月 16 日

Adjunctive Glycine for Obsessive Compulsive Disorder

计划入组 24 人 · 首次发布于 2006 年 11 月 30 日

small molecule therapeutic for autism/obsessive compulsive disorder (Rugen Therapeutics/Allergan)

Fluvoxamine(Luvox)

C₁₅H₂₁F₃N₂O₂ · Rx

Clomipramine(Anafranil)

C₁₉H₂₃ClN₂ · Rx

Brainsway

Israel

THE PARKINSON'S AND MOVEMENT DISORDER INSTITUTE

United States

Vanda Pharmaceuticals

United States

AI-Designed Drug for Alzheimer's Psychosis Enters Clinical Trials

Biohaven Advances Troriluzole in Phase 2/3 Trial for Treatment-Resistant OCD as Pipeline Expands

Internet-Based CBT Shows Promise in Treating OCD During COVID-19 Pandemic